



Stem cell company NextCell Pharma receives approval from Ethics Committee

NextCell Pharma AB (NEXTCL) announced today that approval has been obtained from the Ethics Testing Board EPN, to develop assays from umbilical cord tissue. The collection is performed by regular staff at the clinic at Karolinska University Hospital in Huddinge.

The project is conducted by Edvard Smith, Professor of Molecular Genetics at the Department of Laboratory Medicine at Karolinska Institutet, and one of the founders of the Company. The results may be included in the Company's proprietary intellectual property regarding ProTrans. ProTrans is developed for stem cell therapies for improvement of renal transplantation, as well as inflammatory and autoimmune diseases. In addition, the company may market ProTrans to academic groups or other companies for continued development of new treatments.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Phone: 0702-615 504

E-mail: mathias.svahn@nextcellpharma.com

www.nextcellpharma.com

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on August 8th, 2017.

About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans™, a drug candidate consisting of stem cells, primarily for the treatment of autoimmune and inflammatory diseases as well as for use at kidney transplantations. ProTrans™ consists of stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary Selection Algorithm. In addition, the company provides a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.